1. Home
  2. VCEL

VCEL

Vericel Corporation

Logo Vericel Corporation

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-22-2024 11:31am EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in various therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.

Founded: 1989 Country:
United States
United States
Employees: 314 City: CAMBRIDGE
Market Cap: 2.1B IPO Year: 1997
Target Price: $45.67 AVG Volume (30 days): 467.5K
Analyst Decision: Strong Buy Number of Analysts: 6
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.07 EPS Growth: N/A
52 Week Low/High: $29.24 - $53.05 Next Earning Date: 05-08-2024
Revenue: $197,516,000 Revenue Growth: 20.17%
Revenue Growth (this year): 23.54% Revenue Growth (next year): 25.05%

Share on Social Networks:

Stock Insider Trading Activity of Vericel Corporation (VCEL)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
ZERBE ROBERT L MD VCEL Director Feb 20 '24 Sell $50.01 722 $36,107.22 23,395 SEC Form 4
Wotton Paul K VCEL Director Dec 14 '23 Sell $37.31 5,000 $186,550.00 26,802 SEC Form 4
ZERBE ROBERT L MD VCEL Director Nov 15 '23 Sell $38.06 100 $3,806.00 33,095 SEC Form 4
ZERBE ROBERT L MD VCEL Director Nov 15 '23 Sell $38.00 200 $7,600.00 33,195 SEC Form 4